NK NantKwest Inc.

1.16
-0.08  -6%
Previous Close 1.24
Open 1.23
Price To Book 0.63
Market Cap 91741771
Shares 79,087,734
Volume 890,522
Short Ratio
Av. Daily Volume 601,177

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

90% Disease Control with Median Overall Survival of 9.5 Months - noted - November 7, 2018.
haNK
Pancreatic cancer vaccine
80% Disease Control noted - November 7, 2018.
haNK
Triple Negative Breast Cancer (TNBC)
Phase 2 initiation announced January 9, 2018.
haNK + avelumab + N-803
Merkel cell carcinoma (MCC)

Latest News

  1. NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
  2. Will NantKwest Continue to Surge Higher?
  3. NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
  4. NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
  5. NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
  6. Our Take On NantKwest, Inc.’s (NASDAQ:NK) CEO Salary
  7. Is the Options Market Predicting a Spike in NantKwest (NK) Stock?
  8. NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natural Killer haNKⓇ Cell Therapy with Superagonist IL-15 Cytokine Therapy and PD-L1 Checkpoint Inhibitor Therapy
  9. Soon-Shiong’s NantCell gets $30 million from Celgene
  10. NantKwest to Host 4th Annual Investor/Analyst Day Highlighting Industry Leading R&D and Clinical Programs
  11. Have Insiders Been Selling NantKwest, Inc. (NASDAQ:NK) Shares?
  12. Is Nantkwest Inc (NK) Going to Burn These Hedge Funds?
  13. NantKwest to Present Updated Preclinical Data at the 60th Annual Meeting of the American Society of Hematology
  14. Here's Why NantKwest Skyrocketed 26.4% Today
  15. Healthcare Stocks are Gaining Ground in Technology Niche: Premier Health Group, Inc. (OTC: PHGRF) (CSE: PHGI), Inovalon Holdings, NantKwest Inc.
  16. NantKwest Announces Promising First in Human Clinical Results of 300 Doses Of CD16 Targeted, Off-The-Shelf Cryopreserved Natural Killer Cells (haNK) in a Novel Cancer Memory Vaccine Immunotherapy
  17. NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
  18. NantKwest Sees Hammer Chart Pattern: Time to Buy?
  19. NantKwest to Present at 2018 Cantor Global Healthcare Conference